RxDoctor Payments DataLook up a doctor →

Sanjoy Bhattacharya, MD

Clinical Cardiac Electrophysiology · Phoenix, AZNPI 1710150693

Payments from drug & device makers

$41,662in general payments, 2019–2025

Across 408 payments — averaging $102.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$21K
  • AbbVie$9K
  • Medtronic$4K
  • Boston Scientific$3K
  • Novartis$787
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$682
  • plus $4K from 33 others

What the payments were for

  • Consulting fees$20,73450%
  • Speaking & faculty fees$1,7004%
  • Travel & lodging$3,9079%
  • Food & beverage$15,31737%
  • Education$50%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,662 in reported general payments places this provider in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

See all clinical cardiac electrophysiology providers in Arizona

Medicare billing

Part B allowed, 2024
$502,341
Medicare patients
914
Services billed
4,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban444$559,491
XareltoRivaroxaban72$101,307
FarxigaDapagliflozin Propanediol72$78,027
EntrestoSacubitril/Valsartan49$76,171
JardianceEmpagliflozin44$69,077
MultaqDronedarone Hcl31$59,359
Repatha SureclickEvolocumab20$15,959
Metoprolol Succinate337$7,587
Atorvastatin Calcium379$3,705
Carvedilol390$3,569
Flecainide Acetate51$2,672
Ezetimibe88$2,162
Rosuvastatin Calcium121$2,139
Bumetanide36$1,967
Losartan Potassium246$1,945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$82$559,491444 claims
Johnson & JohnsonXarelto$344$101,30772 claims
AstraZenecaFarxiga$291$78,02772 claims
NovartisEntresto$787$76,17149 claims
Boehringer IngelheimJardiance$255$69,07744 claims
Sanofi-aventis U.S. LLCMultaq$72$59,35931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 80 clinical cardiac electrophysiology providers in Arizona.

Other clinical cardiac electrophysiology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →